FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414906645> ?p ?o ?g. }

• W2414906645 abstract "Background Deferasirox is approved for the treatment of transfusional iron overload in thalasesmia disease. However, in real life, deferasirox is also used as an iron chelator for iron overload in other pathologies, such as myelodysplastic syndrome (MDS). Purpose Our aim was to describe the effectiveness and safety of deferasirox in the treatment of transfusional iron overload in MDS in clinical practice. Material and methods A longitudinal, retrospective, observational study was carried out in a university hospital. We included MDS patients who were treated with deferasirox for transfusion dependent iron overload during the period of study (from January 2011 to April 2015). Treatment effectiveness was assessed by serum ferritin (SF) and liver iron concentration (LIC), measured by MRI. Adverse events and reasons for treatment discontinuation were collected from clinical records. The percentage of patients that had laboratory values for liver enzymes, bilirubin, glomerular filtration rate (GFR) and haemoglobin falling outside of the normal ranges during the treatment was also registered. Results 35 patients were included (50.0% men). Median (p25, p75) SF at baseline was 1636 µg/L (1100, 1634), which fell to 1399 µg/L (824, 1772) during follow-up. Median LIC was 6.4 mg/g (5.2, 12.5) at baseline and 4.6 mg/g (3.1, 6.1) during follow-up. Median treatment duration during the period of study was 11.0 months (3.0, 37.8). 57.1% of patients discontinued deferasirox therapy. Reasons for treatment discontinuation were: renal toxicity (35.0%), exitus (25.0%), maintained SF below 500 µg (15.0%), discontinuation of blood transfusions (10.0%), gastrointestinal intolerance (5.0%) and clinical worsening (5.0%). Treatment discontinuation data were missing in 5% of cases. Among those patients that had a baseline value of AST within the normal range when treatment was initiated, 13.6% had a serum AST level >38 U/L, 29.2% had ALT >42 U/L and 37.5% had bilirubin >1.1 mg/dL during follow-up. Renal function worsened in 40% of patients who had a GFR Conclusion Deferasirox was effective in most of the patients with a reduction in SF and LIC. Renal toxicity was the most frequent adverse event and it was the first reason for treatment discontinuation. No conflict of interest." @default.
• W2414906645 created "2016-06-24" @default.
• W2414906645 creator A5028883496 @default.
• W2414906645 creator A5034220805 @default.
• W2414906645 creator A5037280117 @default.
• W2414906645 creator A5048803850 @default.
• W2414906645 creator A5053199359 @default.
• W2414906645 creator A5059864125 @default.
• W2414906645 creator A5070656920 @default.
• W2414906645 creator A5078047464 @default.
• W2414906645 creator A5082744602 @default.
• W2414906645 creator A5083159896 @default.
• W2414906645 date "2016-02-14" @default.
• W2414906645 modified "2023-10-17" @default.
• W2414906645 title "DI-002 Effectiveness and safety of deferasirox in the treatment of transfusional iron overload in myelodysplastic syndrome in clinical practice" @default.
• W2414906645 doi "https://doi.org/10.1136/ejhpharm-2016-000875.269" @default.
• W2414906645 hasPublicationYear "2016" @default.
• W2414906645 type Work @default.
• W2414906645 sameAs 2414906645 @default.
• W2414906645 citedByCount "0" @default.
• W2414906645 crossrefType "journal-article" @default.
• W2414906645 hasAuthorship W2414906645A5028883496 @default.
• W2414906645 hasAuthorship W2414906645A5034220805 @default.
• W2414906645 hasAuthorship W2414906645A5037280117 @default.
• W2414906645 hasAuthorship W2414906645A5048803850 @default.
• W2414906645 hasAuthorship W2414906645A5053199359 @default.
• W2414906645 hasAuthorship W2414906645A5059864125 @default.
• W2414906645 hasAuthorship W2414906645A5070656920 @default.
• W2414906645 hasAuthorship W2414906645A5078047464 @default.
• W2414906645 hasAuthorship W2414906645A5082744602 @default.
• W2414906645 hasAuthorship W2414906645A5083159896 @default.
• W2414906645 hasConcept C126322002 @default.
• W2414906645 hasConcept C141071460 @default.
• W2414906645 hasConcept C197934379 @default.
• W2414906645 hasConcept C2777218474 @default.
• W2414906645 hasConcept C2777799968 @default.
• W2414906645 hasConcept C2778248108 @default.
• W2414906645 hasConcept C2778715236 @default.
• W2414906645 hasConcept C2780007613 @default.
• W2414906645 hasConcept C2780817109 @default.
• W2414906645 hasConcept C2781053155 @default.
• W2414906645 hasConcept C71924100 @default.
• W2414906645 hasConcept C90924648 @default.
• W2414906645 hasConceptScore W2414906645C126322002 @default.
• W2414906645 hasConceptScore W2414906645C141071460 @default.
• W2414906645 hasConceptScore W2414906645C197934379 @default.
• W2414906645 hasConceptScore W2414906645C2777218474 @default.
• W2414906645 hasConceptScore W2414906645C2777799968 @default.
• W2414906645 hasConceptScore W2414906645C2778248108 @default.
• W2414906645 hasConceptScore W2414906645C2778715236 @default.
• W2414906645 hasConceptScore W2414906645C2780007613 @default.
• W2414906645 hasConceptScore W2414906645C2780817109 @default.
• W2414906645 hasConceptScore W2414906645C2781053155 @default.
• W2414906645 hasConceptScore W2414906645C71924100 @default.
• W2414906645 hasConceptScore W2414906645C90924648 @default.
• W2414906645 hasLocation W24149066451 @default.
• W2414906645 hasOpenAccess W2414906645 @default.
• W2414906645 hasPrimaryLocation W24149066451 @default.
• W2414906645 hasRelatedWork W11447195 @default.
• W2414906645 hasRelatedWork W17747543 @default.
• W2414906645 hasRelatedWork W17800881 @default.
• W2414906645 hasRelatedWork W19428625 @default.
• W2414906645 hasRelatedWork W19430376 @default.
• W2414906645 hasRelatedWork W19887974 @default.
• W2414906645 hasRelatedWork W20076629 @default.
• W2414906645 hasRelatedWork W3197746 @default.
• W2414906645 hasRelatedWork W4582094 @default.
• W2414906645 hasRelatedWork W9644449 @default.
• W2414906645 isParatext "false" @default.
• W2414906645 isRetracted "false" @default.
• W2414906645 magId "2414906645" @default.
• W2414906645 workType "article" @default.